Pharming and partner Valeant (VRX-NC) announced that the Phase II HAE prophylaxis study has been fully enrolled and data are expected by the end of 2Q16. We believe these data could be instrumental in driving Ruconest's market differentiation as Valeant continues its blocking and tackling in the acute setting, including its pure recombinant properties, and expect the likely initiation of a Phase III.

Visit our Analyst Coverage & Reports page to read more reports by ROTH Capital Partners.

Contact

Sijmen de Vries, CEO: T: +31 524 7400

'This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature'

Pharming Group NV issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 15:13:02 UTC

Original Document: http://www.pharming.com/archives/2618